{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:08:06Z","timestamp":1792267686737,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.lungcan.2020.05.018","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T02:49:34Z","timestamp":1590029374000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer"],"prefix":"10.1016","volume":"146","author":[{"given":"Ruoshi","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiao N. Martins","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhu-An","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Ludkovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibha","family":"Raghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cabanero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Moghal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha B.","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Sacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances A.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yasufuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Sound","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.lungcan.2020.05.018_bib0005","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK -positive lung Cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"10072","key":"10.1016\/j.lungcan.2020.05.018_bib0010","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.lungcan.2020.05.018_bib0015","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in untreated ALK -positive non\u2013small cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2020.05.018_bib0020","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2020.05.018_bib0025","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus Crizotinib in ALK-positive non\u2013small cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2020.05.018_bib0030","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2020.05.018_bib0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.lungcan.2017.05.018","article-title":"Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib","volume":"110","author":"Zhu","year":"2017","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2020.05.018_bib0040","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non\u2013small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.lungcan.2020.05.018_bib0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"issue":"120","key":"10.1016\/j.lungcan.2020.05.018_bib0050","doi-asserted-by":"crossref","first-page":"120ra17","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2020.05.018_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-14289-w","article-title":"ALK and IGF-1R as independent targets in crizotinib resistant lung cancer","volume":"7","author":"Wilson","year":"2017","journal-title":"Sci. Rep."},{"issue":"22","key":"10.1016\/j.lungcan.2020.05.018_bib0060","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.1158\/1078-0432.CCR-19-1176","article-title":"Acquired resistance mutations to ALK inhibitors identified by single circulating tumor cell sequencing in ALK-rearranged non\u2013small cell lung cancer","volume":"25","author":"Pailler","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2020.05.018_bib0065","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.lungcan.2020.05.018_bib0070","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/1541-7786.MCR-18-0325","article-title":"Alectinib resistance in ALK-rearranged lung cancer by dual salvage signaling in a clinically paired resistance model","volume":"17","author":"Tsuji","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"6216","key":"10.1016\/j.lungcan.2020.05.018_bib0075","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1126\/science.1254721","article-title":"Patient-derived models of acquired resistance can identify effective drug combinations for cancer","volume":"346","author":"Crystal","year":"2014","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.lungcan.2020.05.018_bib0080","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/j.jtho.2019.07.017","article-title":"Rapid acquisition of alectinib resistance in ALK-positive lung cancer With high tumor mutation burden","volume":"14","author":"Makimoto","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2020.05.018_bib0085","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov."},{"issue":"22","key":"10.1016\/j.lungcan.2020.05.018_bib0090","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2014.60.1492","article-title":"Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma","volume":"33","author":"Stewart","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.05.018_bib0095","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/j.cllc.2018.11.002","article-title":"Identification and development of a lung adenocarcinoma PDX model with STRN-ALK fusion","volume":"20","author":"Ren","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2020.05.018_bib0100","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.lungcan.2018.08.008","article-title":"Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation","volume":"124","author":"Kang","year":"2018","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2020.05.018_bib0105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/JTO.0000000000000087","article-title":"HIP1\u2013ALK, a novel ALK fusion variant that responds to crizotinib","volume":"9","author":"Fang","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2020.05.018_bib0110","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.jtho.2018.06.005","article-title":"Brigatinib in patients with alectinib-refractory ALK-positive NSCLC","volume":"13","author":"Lin","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"22","key":"10.1016\/j.lungcan.2020.05.018_bib0115","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-14-1511","article-title":"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib","volume":"20","author":"Katayama","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.lungcan.2020.05.018_bib0120","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/0008-5472.CAN-11-1340","article-title":"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors","volume":"71","author":"Sasaki","year":"2011","journal-title":"Cancer Res."},{"issue":"5827","key":"10.1016\/j.lungcan.2020.05.018_bib0125","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung Cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.lungcan.2020.05.018_bib0130","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","article-title":"Acquired resistance to TKIs in solid tumours: learning from lung cancer","volume":"11","author":"Camidge","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2020.05.018_bib0135","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1016\/j.jtho.2018.08.2025","article-title":"Identification of a high-level MET amplification in CTCs and cfTNA of an ALK-positive NSCLC patient developing evasive resistance to crizotinib","volume":"13","author":"Berger","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.05.018_bib0140","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00160","article-title":"Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA","author":"Dagogo-Jack","year":"2018","journal-title":"JCO Precis. Oncol."},{"issue":"22","key":"10.1016\/j.lungcan.2020.05.018_bib0145","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1002\/cncr.32422","article-title":"Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: a Canadian reference testing center\u2019s results in population-based reflex testing","volume":"125","author":"Fiset","year":"2019","journal-title":"Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220304414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220304414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:43:49Z","timestamp":1759236229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220304414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":29,"alternative-id":["S0169500220304414"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.05.018","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}